top of page
Bevacizumab treatment for patients with recurrent ovarian cancer
Ovarian cancer is highly prevalent and accounts for high mortality rate among cancers relating to female reproductive system (1). As per...
Dr. Sishir Kumar
Sep 95 min read
Pravastatin vs Atorvastatin: PROVE IT TIMI 22 Study
Cannon CP et al conducted a clinical study (PROVE IT TIMI 22) to assess the benefits of intensive statin therapy vs. moderate statin...
Mrs. Purnima Reddy
Sep 92 min read
Oral Semaglutide vs Empagliflozin: PIONEER 2 Study
Rodbard HW et al conducted the PIONEER 2 clinical study to assess the efficacy of oral Semaglutide in comparison with Empagliflozin in...
Ms. Tanvi Goel
Sep 91 min read
ASCOT-LLA Study: Atorvastatin vs placebo in primary prevention of CHD
Sever PS et al, conducted the ASCOT-LLA study to assess the efficacy of Atorvastatin 10 mg in the prevention of coronary and stroke...
Ms. Roma Joglekar
Sep 92 min read
IRAKLIA Study - Intravenous Isatuximab vs Subcutaneous Isatuximab
The CD38 are present widely and uniformly on the surface of multiple myeloma cells making it a target for many biological therapeutics....
Ms. Roma Joglekar
Sep 92 min read
Oral Semaglutide vs. Sitagliptin: PIONEER 3 Study
Rosenstock J et al. conducted the PIONEER 3 trial to compare the effectiveness of oral Semaglutide against Sitagliptin in adult Type 2...
Ms. Silpa Rani Gajavalli
Sep 92 min read
Rosuvastatin vs Placebo in the prevention of CV events: JUPITER Study
Ridker et al conducted the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)...
Dr. Sishir Kumar
Sep 92 min read
Atorvastatin vs placebo in the primary prevention of CHD: CARDS Study
Colhoun HM, et al. conducted the CARDS ( The Collaborative Atorvastatin Diabetes Study) study, which compared the efficacy of...
Ms. Roma Joglekar
Sep 91 min read
Sacubitril/Valsartan improved Quality of Life in HFrEF patients: PROVIDE HF Study
Heart failure (HF) is a clinical condition characterised by structural or functional abnormality that impairs ventricular filling or...
Dr. Sheetanshu Grover
Sep 94 min read
Sacubitril/Valsartan is well tolerated in patients with HF and renal disorders: TRANSITION Study
Patients with coexisting heart failure (HF) and renal dysfunction (RD) face a significantly poorer prognosis compared to those with HF...
Ms. Reddy Francy Priyanka
Sep 93 min read
Sacubitril/Valsartan showed a greater reduction of NT-proBNP in HFpEF patients: PARAMOUNT Study
Patients with documented left ventricular ejection fraction (LVEF) ≥ 50% are considered to have heart failure (HF) with preserved...
Dr. Anuradha Mallya
Sep 93 min read
Sacubitril/Valsartan reduces HF hospitalizations: PARAGON-HF Study
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricle maintains a normal ejection fraction (≥50%) but...
Ms. Hima Saxena
Sep 94 min read
Cardiovascular outcomes with Semaglutide in high-risk patients
Oral Semaglutide was approved by the FDA in September 2019 to improve blood glucose control in adult patients with type 2 diabetes (1). ...
Ms. Roma Joglekar
Sep 92 min read
LDL-C control with Inclisiran in HeFH patients: ORION 9 study
Heterozygous familial hypercholesterolemia (HeFH) is a prevalent genetic disorder marked by elevated low-density lipoprotein cholesterol...
Ms. Hima Saxena
Sep 94 min read
Inclisiran in patients with ASCVD and elevated LDL-C: ORION 10
Atherosclerotic cardiovascular disease (ASCVD) is a progressive condition characterized by plaque build-up within arterial walls, leading...
Ms. Hima Saxena
Sep 94 min read
Inclisiran in patients with ASCVD and elevated LDL-C: ORION 11
Atherosclerotic cardiovascular disease (ASCVD) is a progressive condition characterized by plaque build-up within arterial walls, leading...
Ms. Hima Saxena
Sep 84 min read
Sacubitril/Valsartan reduces CV mortality and hospitalizations - PARADIGM HF
Heart failure (HF) is a clinical condition where the heart muscle is weakened and cannot pump enough blood to meet the needs of the body...
Dr Mamatha MG
Aug 293 min read
bottom of page